Acquired Company
Enliven Therapeutics, Inc. completed the acquisition of IMARA Inc. from a group of shareholders in a reverse merger on February 23, 2023 for approximately $340 million.
Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. Show more
Start AI Chat
Market Cap
0.00
52 Wk Range
$42.25 - $60.73
Previous Close
$13.75
Open
$14.00
Volume
1,594
Day Range
$13.71 - $14.00
Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Insider Ownership
16.63%
Institutional Own.
81.32%
Qtr Updated
06/30/24
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|